ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons
- PMID:19616072
- DOI: 10.1016/j.neulet.2009.07.032
ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons
Abstract
Apolipoprotein E (ApoE) 4 is a potent risk factor for Alzheimer's disease (AD). However, the mechanism underlying ApoE4 function in the pathology of AD is not well understood. We report here that, in comparison with ApoE2 and ApoE3, ApoE4 significantly reduces levels of insulin-degrading enzyme (IDE), which is responsible for the cellular clearance of Abeta in neurons. This differential regulation of IDE by various ApoE isoforms was blocked by coincubation with N-methyl-d-aspartic acid (NMDA) receptor inhibitors and receptor-associated protein (RAP), which blocked the interaction between ApoE and members of the low-density lipoprotein (LDL) receptor family. Moreover, inhibition of the NMDA receptor increased IDE levels in neurons, while activation of the NMDA receptor-reduced IDE expression. Further studies demonstrate that, as a pathway downstream of the NMDA receptor, cAMP-dependent protein kinase (PKA) contributes to the NMDA receptor-reduced IDE expression. These results suggest that ApoE4 down-regulates IDE expression in neurons by binding to its receptor and stimulating the NMDA receptor pathway, which may account for its role in AD pathogenesis.
Similar articles
- Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes.Rapp A, Gmeiner B, Hüttinger M.Rapp A, et al.Biochimie. 2006 May;88(5):473-83. doi: 10.1016/j.biochi.2005.10.007. Epub 2005 Nov 15.Biochimie. 2006.PMID:16376010
- PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.Du J, Zhang L, Liu S, Zhang C, Huang X, Li J, Zhao N, Wang Z.Du J, et al.Biochem Biophys Res Commun. 2009 Jun 12;383(4):485-90. doi: 10.1016/j.bbrc.2009.04.047. Epub 2009 Apr 19.Biochem Biophys Res Commun. 2009.PMID:19383491
- Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.Song MS, Rauw G, Baker GB, Kar S.Song MS, et al.Eur J Neurosci. 2008 Nov;28(10):1989-2002. doi: 10.1111/j.1460-9568.2008.06498.x.Eur J Neurosci. 2008.PMID:19046381
- NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus.Yamin G.Yamin G.J Neurosci Res. 2009 Jun;87(8):1729-36. doi: 10.1002/jnr.21998.J Neurosci Res. 2009.PMID:19170166Review.
- Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.Fan J, Donkin J, Wellington C.Fan J, et al.Biofactors. 2009 May-Jun;35(3):239-48. doi: 10.1002/biof.37.Biofactors. 2009.PMID:19472365Review.
Cited by
- Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.Inoue Y, Ueda M, Masuda T, Misumi Y, Yamashita T, Ando Y.Inoue Y, et al.Mol Neurobiol. 2019 Dec;56(12):8573-8588. doi: 10.1007/s12035-019-01678-7. Epub 2019 Jul 6.Mol Neurobiol. 2019.PMID:31280448
- Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease.Zhao N, Liu CC, Qiao W, Bu G.Zhao N, et al.Biol Psychiatry. 2018 Feb 15;83(4):347-357. doi: 10.1016/j.biopsych.2017.03.003. Epub 2017 Mar 14.Biol Psychiatry. 2018.PMID:28434655Free PMC article.Review.
- A multi-hit hypothesis for an APOE4-dependent pathophysiological state.Steele OG, Stuart AC, Minkley L, Shaw K, Bonnar O, Anderle S, Penn AC, Rusted J, Serpell L, Hall C, King S.Steele OG, et al.Eur J Neurosci. 2022 Nov;56(9):5476-5515. doi: 10.1111/ejn.15685. Epub 2022 Jun 6.Eur J Neurosci. 2022.PMID:35510513Free PMC article.Review.
- Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.Dorey E, Chang N, Liu QY, Yang Z, Zhang W.Dorey E, et al.Neurosci Bull. 2014 Apr;30(2):317-30. doi: 10.1007/s12264-013-1422-z. Epub 2014 Mar 20.Neurosci Bull. 2014.PMID:24652457Free PMC article.Review.
- Oscillatory hyperactivity and hyperconnectivity in youngAPOE-ɛ4 carriers and hypoconnectivity in Alzheimer's disease.Koelewijn L, Lancaster TM, Linden D, Dima DC, Routley BC, Magazzini L, Barawi K, Brindley L, Adams R, Tansey KE, Bompas A, Tales A, Bayer A, Singh K.Koelewijn L, et al.Elife. 2019 Apr 30;8:e36011. doi: 10.7554/eLife.36011.Elife. 2019.PMID:31038453Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous